Recent Postings to

Worst Pills, Best Pills Newsletter Articles

  View the entire November 2017 issue in PDF format

  • Do Not Use the New Blood Thinner Edoxaban (SAVAYSA)
    (November 2017)
    Learn why edoxaban, one of the new blood thinners approved by the FDA, is not the best option for preventing dangerous blood clots in patients with atrial fibrillation.
  • FDA Cracks Down on Illegal Stem Cell Treatments
    (November 2017)
    Over the past decade, the number of clinics in the U.S. that peddle unproven stem cell "treatments" directly to consumers exploded from a handful in 2010 to as many as 570 in 2016. Find out what the FDA is finally doing to clamp down on the marketing of illegal stem cell treatments.
  • Corticosteroid Injections Not Beneficial for Knee Osteoarthritis
    (November 2017)
    The injection of corticosteroids into the knee joints of patients with osteoarthritis of the knee is a widespread practice. Find out the results of new research funded by the National Institutes of Health showing that such injections actually may accelerate joint damage.
  • Subclinical Hypothyroidism: When to Treat
    (November 2017)
    In this article, we describe a common condition known as subclinical hypothyroidism and discuss which patients with this condition should be treated with thyroid hormone replacement.
  • News Brief for November 2017
    (November 2017)
    In this month’s news brief, we report the FDA’s reckless decision to deny Public Citizen’s petition to ban a dangerous anti-fungal drug.
  • Pregabalin (LYRICA): Neither Effective nor Safe for Treating Sciatica Leg Pain
    (November 2017)
    Doctors often prescribe pregabalin for a neuropathic pain condition known as sciatica, a use that is not approved by FDA. Find out why pregabalin is a bad choice for treating sciatica.

  View the entire October 2017 issue in PDF format

  • U.S. Senate Passes 'False-Hope' Act
    (October 2017)
    In August, the U.S. Senate unanimously passed the so-called Right to Try Act. Worst Pills, Best Pills News Editor Dr. Michael Carome explains how this deceptively named bill would put countless patients at risk by undermining important FDA safety rules related to the use of unapproved, experimental medications.
  • News Brief for October 2017
    (October 2017)
    In this month’s news brief, we report on the FDA’s recent decision to partially grant a petition from Public Citizen to require the addition of a warning about a dangerous drug-drug interaction to product labeling of repaglinide-containing diabetes medications.
  • Tofacitinib (XELJANZ): The Wrong Choice for Rheumatoid Arthritis
    (October 2017)
    Tofacitinib is one of the newer medications approved by the FDA for treatment of rheumatoid arthritis. Learn why we have designated this drug as Do Not Use.
  • Diabetes Drug Canagliflozin Doubles Risk of Amputations, FDA Warns
    (October 2017)
    Canagliflozin is one of three medications in the newest diabetes drug class. In this article, we discuss why the FDA recently required that a black-box warning about the risk of amputations be added to the product labeling of canagliflozin.
  • Vitamin E Does Not Prevent Declines in Memory and Cognitive Function
    (October 2017)
    Dietary supplement makers often tout vitamin E products for a variety of purported health benefits, including the promotion of brain health. Find out why vitamin E supplements are unlikely to prevent cognitive decline and may cause serious harm if taken in doses exceeding the recommended dietary allowance.
  • Injected Naltrexone for Opioid Addiction
    (October 2017)
    Hear how drugmaker Alkermes has engaged in a novel but troubling marketing campaign to increase sales of its once-monthly injected version of naltrexone (VIVITROL) for treatment of opioid addiction.

  View the entire September 2017 issue in PDF format

  • Owner of Drugmaker Linked to Meningitis Outbreak Convicted of Racketeering But Acquitted of Murder
    (September 2017)
    In March 2017, a federal jury found the co-owner of a now-bankrupt Massachusetts compounding pharmacy guilty on more than 50 counts of racketeering and mail fraud for his role in the deadly nationwide fungal meningitis outbreak in 2012, which had been linked to tainted steroid drugs. Read the troubling details of how the company’s co-owner escaped being convicted of second-degree murder.
  • A Dangerous Proposal to Roll Back Pharmacy Compounding Rules
    (September 2017)
    Following a deadly fungal meningitis outbreak linked to a Massachusetts compounding pharmacy’s tainted steroid drugs, Congress in 2013 passed a law to strengthen the FDA’s oversight of the compounding pharmacy industry. Learn about reckless legislation now being considered by Congress that would reverse the 2013 law.
  • New Evidence Refutes Testosterone Benefits for Age-Related Symptoms
    (September 2017)
    In this article, we discuss new data from well-designed randomized controlled trials that show that testosterone treatment in older men with low testosterone blood levels does not improve memory or other cognitive functions and actually increases the buildup of cholesterol in coronary arteries.
  • Naltrexone-Bupropion (CONTRAVE): Another Dangerous Weight-Loss Drug
    (September 2017)
    Learn why Public Citizen’s Health Research Group has designated CONTRAVE, a combination weight-loss medication that was approved by the FDA in 2014, as Do Not Use.
  • Black-Box Warning Added to Hepatitis C Drugs
    (September 2017)
    The FDA recently required that the product labeling for several of the newest hepatitis C drugs be revised to include a black-box warning, the strongest warning that the agency can require. Find out what the new warning says.
  • Abuse-deterrent Opioids
    (September 2017)
    To address the growing epidemic of prescription opioid drug overdoses in the U.S., many drugmakers have attempted to develop opioid pills that are supposedly resistant to being manipulated in ways that make them easier to abuse. In this article, we highlight problems with these so-called abuse-deterrent opioid formulations.
Copyright © 2017 Public Citizen's Health Research Group. All rights reserved.